Next Article in Journal
Smart Poly(lactide)-b-poly(triethylene glycol methyl ether methacrylate) (PLA-b-PTEGMA) Block Copolymers: One-Pot Synthesis, Temperature Behavior, and Controlled Release of Paclitaxel
Next Article in Special Issue
Multicomponent Lipid Nanoparticles for RNA Transfection
Previous Article in Journal
Strategies to Enhance Drug Permeability across Biological Barriers—A Summary of This Important Special Issue
Previous Article in Special Issue
Efficient mRNA Delivery with mRNA Lipoplexes Prepared Using a Modified Ethanol Injection Method
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 4
10.3390/pharmaceutics15041190
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems

by
Adhika Balgobind
,
Aliscia Daniels
,
Mario Ariatti
and
Moganavelli Singh
*
Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(4), 1190; https://doi.org/10.3390/pharmaceutics15041190
Submission received: 2 March 2023 / Revised: 24 March 2023 / Accepted: 6 April 2023 / Published: 8 April 2023
(This article belongs to the Special Issue Liposomal and Lipid-Based Drug Delivery Systems and Vaccines)
Browse Figures
Versions Notes

Abstract

:
The overexpression of the human epidermal growth factor 2 (HER2/neu) oncogene is predictive of adverse breast cancer prognosis. Silencing the HER2/neu overexpression using siRNA may be an effective treatment strategy. Major requirements for siRNA-based therapy are safe, stable, and efficient delivery systems to channel siRNA into target cells. This study assessed the efficacy of cationic lipid-based systems for the delivery of siRNA. Cationic liposomes were formulated with equimolar ratios of the respective cholesteryl cytofectins, 3β-N-(N′, N′-dimethylaminopropyl)-carbamoyl cholesterol (Chol-T) or N, N-dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09), with the neutral helper lipid, dioleoylphosphatidylethanolamine (DOPE), with and without a polyethylene glycol stabilizer. All cationic liposomes efficiently bound, compacted, and protected the therapeutic siRNA against nuclease degradation. Liposomes and siRNA lipoplexes were spherical, <200 nm in size, with moderate particle size distributions (PDI < 0.4). The siRNA lipoplexes exhibited minimal dose-dependent cytotoxicity and effective HER2/neu siRNA transfection in the HER2/neu overexpressing SKBR-3 cells. The non-PEGylated Chol-T-siRNA lipoplexes induced the highest HER2/neu silencing at the mRNA (10000-fold decrease) and protein levels (>111.6-fold decrease), surpassing that of commercially available Lipofectamine 3000 (4.1-fold reduction in mRNA expression). These cationic liposomes are suitable carriers of HER2/neu siRNA for gene silencing in breast cancer.

Graphical Abstract

1. Introduction

Millions of people succumb to cancer annually, breast cancer (BC) being the most prevalent and a major cause of cancer death among women. In 2020, 2.3 million women were diagnosed with BC, with 685,000 deaths worldwide [1]. Breast cancer mortality is a greater challenge in developing countries with poor access to medical treatment. Radiation, surgery, and chemotherapy have been the conventional treatment options. Still, despite advances in the formulation of novel chemotherapeutics, their use has been limited due to systemic toxicities, multidrug resistance, and lack of tumor cell specificity [2].
Overexpression of the HER2/neu oncogene has been found in approximately 30% of all invasive BCs and correlates with more unfettered and destructive tumor growth and greater resistance to cancer chemotherapy [3,4,5]. In HER2/neu amplified breast carcinomas, expression levels are significantly higher, varying from 500,000 to more than 2 million receptors per tumor cell, compared to 25,000 to 185,000 receptors per cell in non-amplified tumors [6,7]. The exploitation of the overexpression of the HER2/neu oncogene can be a potential therapeutic target for BC. Despite recent advances in treatment strategies, most, if not all, conventional treatments, such as chemotherapy, are limited by a lack of specificity for tumor cells and the cell cycle dependence of many chemotherapeutic agents. This has spurred efforts to develop unique anticancer agents with improved molecular target specificity.
Silencing the HER/neu oncogene expression using small interfering RNA (siRNA) may effectively treat patients with HER2/neu overexpressing BC. However, the delivery of therapeutic siRNA to intracellular targets for the induction of sequence-specific mRNA degradation creates an encumbrance that limits the success of siRNA therapeutics. These limitations include the polyanionic nature, hydrophilic character, and relatively high molecular weight, which hampers the direct association of the siRNA to the cell membrane, which creates difficulty in the cellular uptake of these molecules by passive diffusion [8,9]. Furthermore, siRNA molecules in the physiological milieu are prone to degradation by serum nucleases, non-targeted biodistribution, and activation of an immune response, limiting its’ systemic applications [5]. Hence, stable, non-toxic nanocarriers are needed to transport therapeutic siRNA efficiently.
Liposomes have been the most popular of the many lipid-based systems available. Liposomes are vesicles made up of natural membrane constituents and containing an aqueous core. They are biocompatible and biodegradable in vivo, and their by-products are non-toxic [10,11,12], which increased their popularity as efficient siRNA delivery vehicles. Cationic liposomes, due to their positive charge, readily form lipoplexes with the negatively charged siRNA, ensuring favorable intracellular siRNA separation with high transfection and little or no adverse physiological effects [13,14]. The cationic lipids used include a hydrophilic positively charged head group, a lipid hydrophobic tail to anchor the head group to the liposomal membrane bilayer, and a linker to connect the hydrophilic and hydrophobic regions [15,16]. This has led to many novel and interesting cationic lipids being developed over the years [14,17,18,19], including liposomes containing polysaccharides such as chitin and pectin [20]. Of note is the lipid-based siRNA drug partisan (Onpattro), which was approved in 2018 for the treatment of polyneuropathies caused by hereditary transthyretin amyloidosis. This has opened avenues for other siRNA-based nanotherapeutics [21].
When systemically applied, cationic liposomes can activate complement adsorption with plasma proteins [22], resulting in the formation of a protein corona which is recognized and eliminated from circulation by the reticuloendothelial system (RES) or by renal excretion [23]. Hence, liposomes are surface modified by incorporating biocompatible, hydrophilic moieties such as polyethylene glycol (PEG), which provides steric stabilization and ‘masks’ the liposome charge density, preventing opsonization. Hence, the liposome circulation time is increased, and the passive tumor targeting of the liposome is improved [23,24]. However, it was noted that multiple administrations of PEGylated liposomes could lead to increased clearance from the blood, reducing the therapeutic efficiency [25].
This study evaluated the ability of cationic lipid-based carrier systems to deliver target-specific siRNA to breast cancer cells. Cationic cytofectins, 3β-N-(N′, N′-dimethylaminopropyl)-carbamoyl cholesterol (Chol-T) [26] and N, N-dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09) [27] that have been reported previously were used in the liposomal formulation together with DOPE. These liposomes were modified by adding PEG2000 (0–5 mol%) to afford stealth liposomes. The efficacy with which the liposomes-vehiculated siRNA induced silencing of the HER2/neu oncogene overexpression in vitro was assessed at both the mRNA and protein levels using qRT-PCR and western blotting, respectively.

2. Materials and Methods

2.1. Materials

Dioleoylphosphatidylethanolamine (DOPE) and bromophenol blue were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). The 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) was acquired from Avanti Polar Lipids (Alabaster, AL, USA). HyClone® research grade fetal bovine serum (FBS) was purchased from Thermo Scientific (Northumberland, UK). Eagle’s Minimum Essential Medium (EMEM) containing L-glutamine (4.5 g L−1), trypsin-EDTA mixture [versene (EDTA) 200 mg L−1 and trypsin 170,000 U L−1] and antibiotics (100×) containing penicillin G (10,000 U mL−1), streptomycin sulfate (10,000 µg mL−1) were purchased from Lonza BioWhittaker (Verviers, Liège, Belgium). The human embryonic kidney (HEK293) and breast adenocarcinoma (SKBR-3 and MCF-7) cell lines were sourced directly from the American Type Culture Collection (ATCC) (Manassas, VA, USA). All sterile tissue culture plastic consumables were obtained from Corning Incorporated (Corning, NY, USA). The siGENOME non-targeting siRNA #1 (D-001210-01-20) and ON-TARGETplus SMARTpool, and Human ERBB2 (2064) (L-003126-00-0020) target sequences were obtained from Thermo Scientific (Dharmacon, Lafayette, CO, USA). Agarose, ReadyPrepTM protein extraction kit, 10× Tris/glycine/SDS buffer, 5× transfer buffer, blotting-grade blocker, Tween 20, Trans-Blot® TurboTM transfer system RTA transfer kit, mini-PROTEAN® TGXTM long shelf life precast gels, 2× Laemmli sample buffer, Precision Plus ProteinTM dual extra standards, clarity Western ECL substrate and RT-PCR strip tubes were purchased from Bio-Rad Laboratories (Richmond, CA, USA). TRIzol® Reagent, Lipofectamine® 3000, high capacity cDNA Reverse Transcription Kit with RNase inhibitor, MicroAmp® Fast optical 96-well reaction plates, MicroAmp® optical adhesive films, and DNase/RNase free distilled water were purchased from Life Technologies (Carlsbad, CA, USA). The Neu monoclonal antibody (MW 185 kDa), β-Actin (C4) monoclonal antibody (MW 43 kDa), and goat anti-mouse IgG-HRP secondary antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). All other chemicals and general reagents were of analytical grade or higher and purchased from Merck (Darmstadt, Germany) with 18 MΩ water (Milli-Q50) used in preparations.

2.2. Liposome Preparation

Cationic liposomes and PEGylated cationic liposomes were prepared using the thin film evaporation method [28]. The two cationic cholesteryl cytofectins (CCC), Chol-T and MS09, were previously synthesized in the laboratory and reported [26,27]. The composition and molar ratio of the liposomal formulations used in the present study are outlined in Table 1. PEGylated liposomes were formulated with 2 or 5 mol% of PEG. The lipid mixture was vortexed and rotor-evaporated (Büchi RE121 Rotavapor, Büchi, Switzerland) to a thin film, which was hydrated overnight at 4 °C in 500 μL sterile HEPES buffered saline (HBS, 20 mM HEPES, 150 mM NaCl; pH 7.5). The sample was then vortexed and sonicated for 5 min at 21 °C and stored at 4 °C.

2.3. Liposome: siRNA Complex Preparation

Lipoplexes were freshly prepared by adding the siRNA to varying amounts of the cationic liposome suspensions to obtain different (w/w) ratios. The reaction mixtures were briefly vortexed and incubated at room temperature for 30 min to allow for lipoplex formation.

2.4. Characterization

2.4.1. Transmission Electron Microscopy (TEM)

The morphology of the cationic liposomes and lipoplexes (at optimal binding ratios) was examined by cryo-TEM. Liposomes or lipoplexes (2 µL) were deposited onto a formvar-coated copper grid (Ted Pella Inc., Redding, CA, USA) and contrasted 1:1 (v/v) with 4% saturated acidic uranyl acetate. The grids were plunged into liquid nitrogen at −180 °C using an injector system (Leica Microsystems EM CPC, Buffalo Grove, IL, USA), and the samples were examined using a JEOL JEM-1010 electron microscope (Jeol, Tokyo, Japan) operating at an accelerating voltage of 100 kV. The images were captured using the associated Soft Imaging System (SIS) MegaView III, bearing a side-mounted 3-megapixel digital camera.

2.4.2. Size, Zeta Potential, and Polydispersity Index

The hydrodynamic size, zeta potential, and polydispersity index (PDI) of the liposomes and lipoplexes were determined by dynamic light scattering (DLS) on a Malvern Nano-ZS ZetaSizer (Malvern Instruments, Worcestershire, UK), equipped with a 5 mW He-Ne laser beam (633 nm, fixed backscattering detection optics positioned at 173°) at 25 °C. All measurements were done in triplicate. All data were analyzed using the ZetaSizer software version 6.30 (Malvern Instruments, Worcestershire, UK).

2.5. Band-Shift Assay

This assay was used to determine the optimum binding of the siRNA to the cationic liposomes and prepared as previously described [29]. The siRNA: cationic liposomes (w/w) preparations are presented in Table 2, with siRNA kept constant at 0.32 µg. Lipoplexes were loaded into the wells of a 2% agarose gel and electrophoresed at 50 V for 30 min. Gels were visualized, and images were captured on a Vacutec Syngene G: Box BioImaging System (Syngene, Cambridge, UK) using GeneSnap Imaging Software version 7.05 (Syngene, Cambridge, UK). Naked siRNA served as a positive control.

2.6. Serum Nuclease Protection Assay

The siRNA lipoplexes at sub-optimum, optimum, and supra-optimum weight ratios obtained for the band shift assay were used (Table 3). After incubation, the lipoplexes were treated with fetal bovine serum (FBS) to a final concentration of 10% and incubated at 37 °C for 4 h. The reaction was terminated with 10 mM EDTA, and lipoplexes disassociated using 0.5% SDS. After incubation for 20 min at 55 °C, the samples were subjected to agarose gel electrophoresis as in Section 2.5. Control samples included untreated siRNA and FBS-treated siRNA.

2.7. Cell Viability Studies

The cytotoxicity of the lipoplexes was assessed in the HEK293, MCF-7, and SKBR-3 cells using the MTT assay. Cells were seeded at a density of 2.0 × 104 cells per well into 48-well cell plates containing 0.25 mL of complete medium (EMEM supplemented with 10% (v/v) FBS and 1% antibiotics) and incubated at 37 °C for 24 h. The siRNA lipoplexes were prepared as in Section 2.3 and Table 3. After incubation, the medium was replaced, and the lipoplexes were added to the cells. The cells were incubated at 37 °C for 48 h, after which the medium was removed and replaced with 25 µL of MTT (5 mg. mL−1 in PBS) in 0.25 mL medium. The cells were incubated for an additional 4 h at 37 °C, after which the MTT-containing medium was aspirated, and DMSO (0.2 mL) was added to dissolve the formazan crystals. Untreated cells were used as the positive control (100% cell viability), together with a Lipofectamine® 3000 control at its optimal concentration as per manufacturer’s protocol. All assays were conducted in triplicate. Absorbance was measured at 570 nm using a Vacutec, Mindray MR-96A microplate reader, with DMSO as a blank. The cell viability (%) was then calculated using Equation (1):
% Cell survival (CS) = Average of treated cells/Average of control cells × 100

2.8. HER2/neu Silencing at mRNA and Protein Levels

2.8.1. siRNA Transfection

Four different sequences of 19 nucleotides (ON-TARGETplus SMARTpool) were used as potential siRNAs targeting the HER2/neu gene. A non-targeting sequence siRNA was used as a non-specific siRNA control. The SKBR-3 cells were seeded into 6-well plates at a density of 1 × 105 cells per well and incubated at 37 °C for 24 h. The medium was then replaced with 1.5 mL fresh complete medium, followed by adding 10 μL of the siRNA lipoplexes (Table 3), with siRNA maintained at 0.64 µg. Controls included untreated cells and Lipofectamine® 3000 (positive transfection control), where lipoplexes were prepared according to the manufacturer’s instructions (5 µL Lipofectamine® 3000 reagent and 2.5 µL siRNA (0.64 µg) in 250 µL EMEM for 5 min at room temperature). All assays were done in triplicate. Post 48 h and 72 h transfection, the cells were harvested for assessing HER2/neu gene silencing using qRT-PCR and western blotting, respectively.

2.8.2. RNA Extraction and qRT-PCR

Total cellular RNA from the SKBR-3 cells was extracted using TRIzol® Reagent following the manufacturer’s protocol. The RNA pellet was resuspended in 30 μL RNase-free water. The total RNA was converted into cDNA by reverse transcriptase PCR using the high-capacity cDNA Reverse Transcription (RT) Kit with RNase inhibitor, following the manufacturer’s protocol. Gene expression was quantified by qRT-PCR using the TaqMan® gene expression assays, which are FAMTM dye-labeled and possess a minor-groove binding (MGB) probe. The primers and probe used were the genes of interest HER2/neu (Assay ID Hs01001580_m1) and the endogenous control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Assay ID Hs03929097_g1). Singleplex PCR reactions were conducted as triplicates for all samples. Each reaction mixture (20 μL) contained 10 μL TaqMan® gene expression master mix (AmpliTaq Gold® DNA polymerase, deoxyribonucleotide triphosphates (dNTPs) with deoxyuridine triphosphate (dUTP), UP (Ultra Pure), Uracil-DNA glycosylase (UDG), ROXTM passive reference, as well as buffer components optimized for specificity, sensitivity, and precision), 1 μL 20× TaqMan® gene expression assay mix, and 9 μL sample cDNA. The qRT-PCR was performed under the following conditions: 95 °C for 10 min (hold), followed by 40 cycles of 95 °C for 15 s (denature) and 60 °C for 1 min (anneal/extend) on a BioRad CFX 96TM Real-Time System, C1000 TouchTM Thermal Cycler using CFX Manager Software version 3.0. (Hercules, CA, USA) Relative expression values of HER2/neu mRNA normalized to the level of GAPDH mRNA were determined using the 2−∆∆Ct method [30].
Fold difference = 2−∆∆Ct
∆Ct sample − ∆Ct calibrator = ∆∆Ct
Ct GOI s − Ct norm s = ∆Ct sample
Ct GOI c − Ct norm c = ∆Ct calibrator
where s represents the sample, c the calibrator (untreated cells), GOI the gene of interest HER2/neu, and norm the normalizer gene GAPDH.

2.8.3. Protein Extraction and Western Blotting

The extraction of total cellular proteins was performed 72 h after transfection, using the ReadyPrepTM Protein Extraction Kit, according to the manufacturer’s specifications (Bio-Rad, Hercules, CA, USA), and quantified using a NanoDrop 2000c spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Approximately 20 μg of protein were treated with an equal volume of 2× Laemmli sample buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 125 mM Tris-HCl, pH 6.8) and heated at 95 °C for 5 min. Before loading, Mini-PROTEAN® TGXTM (10%) long shelf life precast gel cassettes (Bio-Rad Laboratories, Richmond, CA, USA) were placed in a Bio-Rad Mini-PROTEAN® Tetra System, with the upper tank containing chilled 1× Tris/glycine/SDS running buffer (25 mM Tris, 190 mM glycine, and 0.1% (w/v) SDS, pH 8.3, Bio-Rad Laboratories, Richmond, CA, USA)., and the lower tank filled with chilled 1× Tris/glycine/SDS running buffer. The protein samples were loaded into the wells, and electrophoresis was conducted at room temperature for 30 min at 200 V cm−1. A molecular weight marker (3 μL) (Precision Plus ProteinTM dual extra standards) was loaded into the first well. Following electrophoresis, protein transfer (blotting) was conducted using the Bio-Rad Trans-Blot® TurboTM transfer system and RTA transfer kits following the manufacturer’s protocol. The transfer was performed at 2.5 A, 25 V for 10 min to promote high Mw transfer (>150 kDa). The blot and gel were then placed in deionized water. Before antibody incubation, unoccupied sites on the blot were saturated in a solution of 3% blotting-grade blocker (non-fat dry milk) in Tris-buffered saline (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.1% Tween 20 (TBST) for 1 h at room temperature. The membranes were incubated overnight at 4 °C in TBST containing either Neu, a mouse monoclonal antibody raised against a synthetic peptide corresponding to amino acids 1242–1255 of human Neu (1:5000) for HER2/neu protein detection, or β-Actin (1:200) used as an internal control for protein loading. The following day, the primary antibody was removed, and the membranes were washed in 20 mL TBST with agitation for 5 min (5×). The membranes were then incubated at room temperature in goat anti-mouse IgG-HRP secondary antibody (1:2000 in TBST). After 1 h, the secondary antibody was decanted, and the membranes were washed in 20 mL TBST with agitation for 5 min (5×). The membranes were developed using a ClarityTM Western ECL substrate kit following the manufacturer’s instructions. The blots were incubated for 5 min at room temperature and then visualized using a Bio-Rad digital imager ChemiDocTM MP system. Band intensity was determined using Image Lab Software version 5.2.2 (BioRad, Hercules, CA, USA).

2.9. Statistical Analysis

Data are presented as means ± SD (n = 3). Statistical Analysis among mean values was performed using one-way ANOVA followed by the Tukey-Kramer multiple comparisons test between formulations. All statistics were performed using a 95% confidence interval and were considered significant when the p-value was less than 0.05 (p < 0.05).

3. Results

3.1. Liposome and Lipoplex Characterization

Cryo-TEM enabled the direct examination of the ultrastructure of the colloidal carriers in their frozen-hydrated state. Figure 1A–F presents the TEM micrographs of the Chol-T and MS09 lipoplexes with siRNA. The images revealed a heterogeneous population of typically spherical or ellipsoidal structures with a bilayered membrane surrounding the internal aqueous core. The lipoplexes appeared well dispersed with little aggregation.
DLS measurements revealed nanometer (nm) sized particles which were accompanied by moderate to narrow polydispersity indices (PDI) and good zeta (ζ) potentials, as summarized in Table 4. For Chol-T, sizes ranged from 71.64 nm to 121.07 nm, while the lipoplexes ranged from 149.61 nm to 187.97 nm. The MS09 liposomes and lipoplexes were slightly smaller (65.47 nm to 113.02 nm and 103.24 nm to 169.13 nm, respectively). The MS09-based lipoplexes also exhibited better zeta potentials (16.08 mV to 53.21 mV) than the Chol-T-based lipoplexes. For both liposomes, a size reduction upon functionalization was noted. Furthermore, functionalization with PEG reduced the zeta potential, especially in the Chol-T-based liposomes and lipoplexes.

3.2. Liposome Binding and Protection Efficiencies

The agarose gel migration patterns illustrated that all liposomal formulations effectively bound the siRNA, as seen in Figure 2. The complete or endpoint binding ratios of the siRNA by the cationic liposomes are represented in Table 5. Ratios below the optimum exhibited bands that fluoresced brightly and then gradually lightened until the band completely disappeared, signifying that the negatively charged siRNA was neutralized entirely at those respective N/P charge ratios.
The nuclease protection assay showed the ability of the cationic liposomes to protect their siRNA cargo from degradation (Figure 3). The positive controls (lanes 1) and negative controls (lanes 2) assessed the degree of serum nuclease digestion of the lipoplexes. Both non-PEGylated lipoplexes offered better protection to their siRNA cargo than their PEGylated counterparts (Figure 3A).

3.3. Cell Viability Assay

The 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to assess the viability of cells exposed to the transfection complexes (Figure 4). All cells maintained a viability of over 70%, except for the SKBR-3 cells exposed to MS09 5% PEG2000 lipoplexes which showed a 50% decrease in cell viability (p < 0.001). Figure 4A,B shows that for the HEK293 and MCF-7 cells, a dose-dependent cytotoxic effect with an increase in charge ratios was observed. The MS09-based lipoplexes were slightly less toxic than the Chol-T -based lipoplexes in the HEK293 cells (Figure 4A). The MS09: siRNA lipoplexes at N/P ratios of 4.9 and 5.4 were non-toxic to the HEK293 cells and produced improved cell viability (>100%). In the SKBR-3 cells, a dose-independent decrease in cell viability was observed for the MS09-based lipoplexes, and in some instances, MS09 was slightly more toxic than Chol-T. This was seen for the MS09 lipoplex containing 5% PEG, where cell viability was slightly above 50%. Nevertheless, all other lipoplexes produced cell viability above 70%.

3.4. HER2/neu Gene Silencing in SKBR-3 (Breast Cancer) Cells

3.4.1. Real-Time Quantitative PCR (qRT-PCR)

According to the qRT-PCR results depicted in Figure 5, the calibrator revealed high HER2/neu gene levels. The NT-siRNA showed no knockdown, whereas the uncomplexed HER2/neu target siRNA resulted in a slight decrease of the HER2/neu gene at the mRNA level. The gene expression levels of the housekeeping normalizer gene GAPDH did not differ significantly among the control and test samples. Each liposomal formulation could efficiently deliver the siRNA against the HER2/neu oncogene in the SKBR-3 BC cells in the presence of serum, as indicated by the downregulation of HER2/neu at the mRNA level (p < 0.001). A comparison of the non-PEGylated Chol-T and MS09 lipoplexes at the different charge ratios revealed that Chol-T:siRNA lipoplexes induced the highest HER2/neu silencing effect at all concentrations (p < 0.001), exceeding that of Lipofectamine®-3000 (4.1- fold decrease).

3.4.2. HER2/neu Protein Expression

The HER2/neu protein expression levels were analyzed using western blotting. Results were analyzed based on densitometric values, and β-actin control was used to determine the normalization or equivalency of lane loading. High levels of HER2/neu protein expression (ratios) in negative control treatments relative to β-actin (Figure 6A) were observed. In contrast, dramatic decreases in HER2/neu protein expression levels were observed for all the siRNA delivery systems employed in this study.
The non-PEGylated Chol-T and MS09 liposomes resulted in a dose-dependent decrease in HER2/neu protein expression, with an increase in the N/P charge ratio causing a reduction in protein expression. Chol-T lipoplexes exhibited a higher decrease in protein expression compared to the MS09 lipoplexes. Normalized HER2/neu protein expression levels decreased by: 53.50, 56.48, and 51.89-fold (Chol-T 2% PEG2000); 41.29, 41.96, and 48.28 (Chol-T 5% PEG2000); 14.18, 17.60 and 22.61 (MS09 2% PEG2000); 6.94, 15.55 and 16.68 (MS09 5% PEG2000) compared to the untreated SKBR-3 cells. Figure 7A further highlights the significant silencing of the HER2/neu gene in cells treated with Chol-T nanocomplexes against the Lipofectamine® control. This knockdown is also much greater than that for the MS09 lipoplexes (Figure 7B).

4. Discussion

Both cationic liposomes were previously synthesized and characterized, and their complexes with DNA were described as clusters of spherical liposomes [26,27], as observed in the current study. However, some variations were noted, which could be due to the amorphous nature or flexibility of the liposomal membranes. The surface modifications of the liposomal vesicles with PEG chains are not clear under TEM due to the low contrast of PEG [31].
The size of the liposome influences its cellular interaction and uptake, with sizes of 50–250 nm proposed to bypass elimination and clearance by the RES [32,33]. Our results indicate that the liposomes were relatively stable and homogeneous and are within the size range generally considered ideal for both cellular uptake and systematic circulation [34,35]. Lipoplex formation resulted in a size increase (up to 187.97 nm), possibly due to the binding of the siRNA onto the liposome surface compared to its’ entrapment within the liposomes. The decrease in size and PDI of the Chol-T and MS09 liposomes upon PEGylation may be attributed to the strong inter-bilayer repulsion that can overcome the attractive van der Waals forces, thus providing a steric barrier at the surface of the liposomes. PEG chains are reported to provide steric stabilization, prevent vesicle aggregation and encourage the formation of homogeneous, smaller liposomes with good colloidal stability and biocompatibility [36,37]. The zeta potential indicates the colloidal stability with values < −25 mV or > +25 mV considered stable. The zeta potentials of the liposomes and lipoplexes decreased upon the addition of PEG due to the masking of the positive charges. However, liposomes containing 2% PEG remained highly positive (>20 mV), indicating that the amount, length, and density of the PEG chains can affect the degree of stability offered [38]. It is important that the amount of positive charge present be sufficient to allow for siRNA binding and endosomal escape without affecting its disassociation from the lipoplex [39]. The successful transfection noted confirms the favorable properties of these liposomes. The MS09 5% PEG had higher PDI values, suggesting a slightly polydisperse liposomal population. It was proposed that for liposomes, a PDI of 0.3 is acceptable and indicates a homogenous population of vesicles [40].
More of the PEGylated cationic liposomes were required to completely bind the siRNA, possibly due to the partial masking of the positive charges by PEG. Although the 5% MS09 liposomes could retard the siRNA, no clear endpoint was established. Overall, the liposomes showed good protection of the siRNA in the presence of FBS, with the 5% PEG liposomes offering the least protection. Turetskiy and Coworkers (2017) observed sandwich-like structures for the siRNA lipoplexes and proposed that this improved their ability to protect the nucleic acid from degradation [41]. PEGylated liposomes were proposed to form looser complexes with siRNA, with PEG chains preventing the electrostatic interaction between the siRNA and the cationic lipid [42]. This could lead to the siRNA being exposed on the liposome’s surface and easily attacked by nucleases present in serum. There was also some correlation with the zeta potentials obtained, indicating that liposomal instability can affect the ability of the carrier to protect its cargo from nucleases. A similar serum nuclease digestion profile was reported for DOTAP-based cationic liposomes complexed with a TNF-α-siRNA [43].
The low cytotoxicity observed for these lipoplexes could be attributed to monovalent cationic lipids, which are less toxic than multivalent cationic lipids [44]. Furthermore, it was suggested that monovalent cationic liposomes possess good gene knockout due to their favorable cellular uptake and endosomal escape due to the ion-pair mechanism [25]. The DOPE and cholesterol in the liposomal formulations contributed to the lipoplexes biocompatibility and stability, with cholesterol, a natural biomembrane component known to regulate the fluidity of the lipid bilayer [15,45]. These results are similar to previous reports where an increase in the length of the spacer segment resulted in reduced cytotoxicity in vitro [46]. Moreover, lipid-containing carbamate bonds have lower cytotoxicity, are stable under neutral conditions, and are prone to hydrolysis at low pH (in the endosome) [47,48,49]. The increased cytotoxicity exhibited by the PEGylated lipoplexes was proposed to be due to a higher cationic lipid concentration [50] and the possibility that these lipids generate reactive oxygen species (ROS). Since cancer cells exhibit greater ROS stress than normal cells [51,52], the SKBR-3 cell viability may have affected ROS production.
PEG-based Chol-T lipoplexes produced a reduced HER2/neu mRNA expression, which is in accordance with a previous report where PEGylation of DC-Chol/DOPE siRNA lipoplexes caused a decrease in size and zeta potential, and no HER2 silencing in SKBR-3 cells [50]. However, PEG-based MS09 lipoplexes significantly increased the HER2/neu gene silencing (p < 0.001) despite a size and zeta potential reduction. This may be related to their slightly lower cell viability. The HER2/neu protein expression results corroborated the qRT-PCR findings, suggesting that cationic liposomes bearing shorter aliphatic chains offer better transfection efficiency. It was proposed that increased transfection efficiency with shorter hydrocarbon chains is due to increased bilayer fluidity, leading to enhanced inter-membrane transfer and mixing of the lipid membrane [53]. Although the MS09 lipoplexes did not elicit HER2/neu gene silencing at the same level as the Chol-T lipoplexes, they were still effective. These MS09 liposomes have previously shown significant c-MYC silencing in MCF-7 and HT-29 cells, surpassing that of Lipofectamine®-3000 [54]. Cationic liposomes have also been successfully used to deliver siRNA (siPlk1) to breast cancer cells in vitro [55].
Despite advances in HER2-targeted monoclonal antibody therapy [56], including the use of Trastuzumab or Herceptin [57], the need for chemotherapy is still crucial for breast cancer patients. In addition, the approval of the siRNA drug, Onpattro and its effectiveness in improving nerve function has highlighted the immense potential of RNA interference for the treatment of other disorders. Hence, nanoparticle-mediated gene silencing may be a viable option. Overall, findings from this study encourage future studies and optimizations of these cationic liposomes for their use in gene silencing in cancer.

5. Conclusions

This study highlights the immense potential of both PEGylated and non-PEGylated Chol-T and MS09 cationic liposomes in HER2/neu siRNA oncogene silencing in SKBR-3 cells. The findings support the hypothesis that these non-viral cationic liposome systems can facilitate future-therapeutic siRNA gene delivery. However, with the caveat that PEGylated cationic liposomes be used with caution since their effects varied with each of the cytofectins used in this study. Post-inserting PEG on preformed siRNA lipoplexes is conceivably a viable option to alleviate some of the adverse effects of using PEG. This strategy demonstrates better siRNA binding and the potential for masking siRNAs and protecting them from nuclease digestion. Among the cationic liposomes utilized in this study, non-PEGylated Chol-T lipoplexes induced the highest gene silencing at all tested N/P ratios, as indicated by the significant decrease in gene expression (10,000-fold decrease, p < 0.001). They exceeded the silencing effect obtained by Lipofectamine®-3000 (4.1-fold reduction). Chol-T lipoplexes were well dispersed, colloidally stable, possessed the lowest N/P charge ratio, and exhibited minimal cytotoxicity in the SKBR-3 cells, which may have been attributed to their superior transfection. Given their biocompatibility and excellent transfection efficiency compared to the commercial transfection agent, these cationic liposomes offer a promising and attractive alternative for siRNA gene therapy in vivo. In addition, a combination therapy using siRNA and an anticancer drug can be employed as a further study.

Author Contributions

Conceptualization, M.S., M.A. and A.B.; methodology, A.B.; software, A.B. and A.D.; validation, M.S., M.A. and A.D.; formal analysis, A.B.; investigation, A.B.; resources, M.S. and M.A.; data curation, A.B.; writing—original draft preparation, A.B. and A.D.; writing—review and editing, M.S., A.D. and M.A.; visualization, A.B.; supervision M.S. and M.A.; project administration, M.S. and M.A.; funding acquisition, M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation, South Africa (grant number 129263).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data and contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments

The authors acknowledge colleagues of the Nano-Gene and Drug delivery group for continued advice and technical support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Breast Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. (accessed on 10 January 2023).
  2. Rizvi, S.A.; Saleh, A.M. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm. J. 2018, 26, 64–70. [Google Scholar] [CrossRef] [PubMed]
  3. Menard, S.; Tagliabue, E.; Campiglio, M.; Pupa, S.M. Role of HER2 gene overexpression in breast carcinoma. J. Cell. Physiol. 2000, 182, 150–162. [Google Scholar] [CrossRef]
  4. Núñez, C.; Capelo, J.L.; Igrejas, G.; Alfonso, A.; Botana, L.M.; Lodeiro, C. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials 2016, 97, 34–50. [Google Scholar] [CrossRef]
  5. Padayachee, J.; Daniels, A.; Balgobind, A.; Ariatti, M.; Singh, M. HER2/neu and MYC Gene Silencing in breast cancer: Therapeutic potential and advancement in non-viral nanocarrier systems. Nanomedicine 2020, 15, 1437–1452. [Google Scholar] [CrossRef] [PubMed]
  6. Tsé, C.; Gauchez, A.S.; Jacot, W.; Lamy, P.J. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat. Rev. 2012, 38, 133–142. [Google Scholar] [CrossRef]
  7. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61, 1–13. [Google Scholar] [CrossRef] [PubMed]
  8. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129–138. [Google Scholar] [CrossRef]
  9. Daniels, A.; Singh, M. Sterically stabilized siRNA: Gold nanocomplexes enhance c-MYC in a breast cancer cell model. Nanomedicine 2019, 14, 1387–1401. [Google Scholar] [CrossRef]
  10. Kesharwani, P.; Gajbhiye, V.; Jain, N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33, 7138–7150. [Google Scholar] [CrossRef] [PubMed]
  11. Oh, Y.K.; Park, T.G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 2009, 61, 850–862. [Google Scholar] [CrossRef]
  12. Shim, G.; Kim, M.G.; Park, J.Y.; Oh, Y.K. Application of cationic liposomes for delivery of nucleic acids. Asian, J. Pharm. Sci. 2013, 8, 72–80. [Google Scholar] [CrossRef] [Green Version]
  13. Li, M.; Li, S.; Li, Y.; Yang, G.; Li, M.; Xie, Y.; Su, W.; Wu, J.; Ma, W.; Li, H.; et al. Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer. Eur. J. Med. Chem. 2022, 233, 114198. [Google Scholar] [CrossRef]
  14. Vaidya, S.; Jeengar, M.K.; Wadaan, M.A.; Mahboob, S.; Kumar, P.; Reece, L.M.; Bathula, S.R.; Dutta, M. Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines. Evid.-Based Complement. Altern. Med. 2022, 2022, 9231641. [Google Scholar] [CrossRef]
  15. Tenchov, R.; Bird, R.; Curtze, A.E.; Zhou, Q. Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021, 15, 16982–17015. [Google Scholar] [CrossRef]
  16. Gao, H.; Hui, K.M. Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivatives. Gene Ther. 2001, 8, 855–863. [Google Scholar] [CrossRef] [Green Version]
  17. Elsana, H.; Olusanya, T.O.B.; Carr-wilkinson, J.; Darby, S.; Faheem, A.; Elkordy, A.A. Evaluation of novel cationic gene based liposomes with cyclodextrin prepared by thin film hydration and microfluidic systems. Sci. Rep. 2019, 9, 15120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Hattori, Y.; Tang, M.; Torii, S.; Tomita, K.; Sagawa, A.; Inoue, N.; Yamagishi, R.; Ozaki, K.-I. Optimal combination of cationic lipid and phospholipid in cationic liposomes for gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes. Mol. Med. Rep. 2022, 26, 253. [Google Scholar] [CrossRef]
  19. Domínguez-Arca, V.; Sabín, J.; García-Río, L.; Bastos, M.; Taboada, P.; Barbosa, S.; Prieto, G. On the structure and stability of novel cationic DPPC liposomes doped with gemini surfactants. J. Mol. Liq. 2022, 366, 120230. [Google Scholar] [CrossRef]
  20. Corrie, L.; Gulati, M.; Awasthi, A.; Vishwas, S.; Kaur, J.; Khursheed, R.; Porwal, O.; Alam, A.; Parveen, S.R.; Singh, H.; et al. Harnessing the dual role of polysaccharides in treating gastrointestinal diseases: As therapeutics and polymers for drug delivery. Chem.-Bio.Interact. 2022, 368, 110238. [Google Scholar]
  21. Akinc, A.; Maier, M.A.; Manoharan, M.; Fitzgerald, K.; Jayaraman, M.; Barros, S.; Ansell, S.; Du, X.; Hope, M.J.; Madden, T.D.; et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019, 14, 1084–1087. [Google Scholar] [CrossRef]
  22. Caracciolo, G. Liposome-protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines. Nanomed. Nanotechnol. Biol. Med. 2015, 11, 543–557. [Google Scholar] [CrossRef]
  23. Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S.Y.; Sood, A.K.; Hua, S. Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol. 2015, 6, 286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 2008, 69, 1–9. [Google Scholar] [CrossRef] [PubMed]
  25. Zhen, S.; Li, X. Liposomal delivery of CRISPR/Cas9. Cancer Gene Ther. 2020, 27, 515–527. [Google Scholar] [CrossRef]
  26. Singh, M.; Ariatti, M. Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes. J. Control. Release 2003, 92, 383–394. [Google Scholar] [CrossRef] [PubMed]
  27. Singh, M.; Ariatti, M. A cationic cytofectin with long spacer mediates favourable transfection in transformed human epithelial cells. Int. J. Pharm. 2006, 309, 189–198. [Google Scholar] [CrossRef]
  28. Gao, X.; Huang, L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 1991, 179, 280–285. [Google Scholar] [CrossRef]
  29. Singh, M. Assessing nucleic acid: Cationic nanoparticle interaction for gene delivery. In Bio-Carrier Vectors; Narayanan, K., Ed.; Springer: New York, NY, USA, 2021; Volume 2211, pp. 43–55. [Google Scholar]
  30. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆∆CT method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef] [PubMed]
  31. Kuntsche, J.; Horst, J.C.; Bunjes, H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int. J. Pharm. 2011, 417, 120–137. [Google Scholar] [CrossRef]
  32. Lorenzer, C.; Dirin, M.; Winkler, A.M.; Baumann, V.; Winkler, J. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 2015, 203, 1–15. [Google Scholar] [CrossRef] [Green Version]
  33. Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.P.; Passirani., C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34, 6429–6443. [Google Scholar] [CrossRef]
  34. Kapoor, M.; Burgess, D.J.; Patil, S.D. Physicochemical characterization techniques for lipid-based delivery systems for siRNA. Int. J. Pharm. 2012, 427, 35–57. [Google Scholar] [CrossRef]
  35. Mével, M.; Kamaly, N.; Carmona, S.; Oliver, M.H.; Jorgensen, M.R.; Crowther, C.; Salazar, F.H.; Marion, P.L.; Fujino, M.; Natori, Y.; et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J. Control. Release 2010, 143, 222–232. [Google Scholar] [CrossRef] [PubMed]
  36. Kenworthy, A.K.; Hristova, K.; Needham, D.; McIntosh, T.J. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 1995, 68, 1921–1936. [Google Scholar] [CrossRef] [Green Version]
  37. Needham, D.; McIntosh, T.J.; Lasic, D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta. 1992, 1108, 40–48. [Google Scholar] [CrossRef]
  38. Hassan, S.; Prakash, G.; Ozturk, A.B.; Saghazadeh, S.; Sohail, M.F.; Seo, J.; Dokmeci, M.R.; Zhang, Y.S.; Khademhosseini, A. Evolution and Clinical Translation of Drug Delivery Nanomaterials. Nano Today 2017, 15, 91–106. [Google Scholar] [CrossRef] [PubMed]
  39. Liu, C.; Zhang, L.; Zhu, W.; Guo, R.; Sun, H.; Chen, X.; Deng, N. Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy. Mol. Ther.-Methods Clin. Dev. 2020, 18, 751–764. [Google Scholar] [PubMed]
  40. Danaei, M.; Dehghankhold, M.; Ataei, S.; Davarani, F.H.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018, 10, 57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Turetskiy, E.A.; Koloskova, O.O.; Nosova, A.S.; Shilovskiy, I.P.; Sebyakin, Y.L.; Khaitov, M.R. Physicochemical properties of lipopeptide-based liposomes and theircomplexes with siRNA. Biomed. Khim. 2017, 63, 472–475. [Google Scholar] [CrossRef] [Green Version]
  42. Belletti, D.; Tosi, G.; Forni, F.; Lagreca, I.; Barozzi, P.; Pederzoli, F.; Vandelli, M.A.; Riva, G.; Luppi, M.; Ruozi, B. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. Eur. J. Pharm. Biopharm. 2016, 99, 7–17. [Google Scholar] [CrossRef] [Green Version]
  43. Pandi, P.; Jain, A.; Kommineni, N.; Ionov, M.; Bryszewska, M.; Khan, W. Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA. Int. J. Pharm. 2018, 550, 240–250. [Google Scholar] [CrossRef]
  44. Spagnou, S.; Miller, A.D.; Keller, M. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004, 43, 13348–13356. [Google Scholar] [CrossRef] [PubMed]
  45. Van Gaal, E.V.B.; van Eijk, R.; Oosting, R.S.; Kok, R.J.; Hennink, W.E.; Crommelin, D.J.A.; Mastrobattista, E. How to screen non-viral gene delivery systems in vitro? J. Control. Release 2011, 154, 218–232. [Google Scholar] [CrossRef]
  46. Floch, V.; Loisel, S.; Guenin, E.; Herve, A.C.; Clement, J.C.; Yaouanc, J.J.; des Abbayes, H.; Ferec, C. Cation substitution in cationic phosphonolipids: A new concept to improve transfection activity and decrease cellular toxicity. J. Med. Chem. 2000, 30, 4617–4628. [Google Scholar] [CrossRef] [PubMed]
  47. Boomer, J.A.; Thompson, D.H.; Sullivan, S.M. Formation of plasmid based transfection complexes with an acid-labile cationic lipid: Characterization of in vitro and in vivo gene transfer. Pharm. Res. 2002, 19, 1292–1301. [Google Scholar] [CrossRef]
  48. Liu, D.L.; Hu, J.J.; Qiao, W.H.; Li, Z.S.; Zhang, S.B.; Cheng, L.B. Synthesis of carbamate-linked lipids for gene delivery. Bioorganic Med. Chem. Lett. 2005, 15, 3147–3150. [Google Scholar] [CrossRef]
  49. Monpara, J.; Velga, D.; Verma, T.; Gupta, S.; Vavia, P. Cationic cholesterol derivative efficiently delivers the genes: In silicoand in vitro studies. Drug Deliv. Transl. Res. 2019, 9, 106–122. [Google Scholar] [CrossRef]
  50. Zhang, Y.; Li, H.; Sun, J.; Gao, J.; Liu, W.; Li, B.; Guo, Y.; Chen, J. DC-Chol/DOPE cationic liposomes: A comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int. J. Pharm. 2010, 390, 198–207. [Google Scholar] [CrossRef]
  51. Park, H.S.; Jung, H.Y.; Park, E.Y.; Kim, J.; Lee, W.J.; Bae, Y.S. Cutting edge: Direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J. Immunol. 2004, 173, 3589–3593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Soenen, S.J.H.; Illyes, E.; Vercauteren, D.; Braeckmans, K.; Majer, Z.; De Smedt, S.C.; De Cuyper, M. The role of nanoparticle concentration-dependent induction of cellular stress in the internalization of non-toxic cationic magnetoliposomes. Biomaterials 2009, 30, 6803–6813. [Google Scholar] [CrossRef]
  53. Shi, J.; Yu, S.; Zhu, J.; Zhi, D.; Zhao, Y.; Cui, S.; Zhang, S. Carbamate-linked cationic lipids with different hydrocarbon chains for gene delivery. Colloids Surf. B Biointerfaces 2016, 141, 417–422. [Google Scholar] [CrossRef] [PubMed]
  54. Habib, S.; Daniels, A.; Ariatti, M.; Singh, M. Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro. F1000Research 2020, 9, 770. [Google Scholar] [CrossRef] [PubMed]
  55. Bulbake, U.; Kommineni, N.; Ionov, M.; Bryszewska, M.; Khan, W. Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1siRNA in breast cancer treatment. Pharm. Dev. Technol. 2020, 25, 9–19. [Google Scholar]
  56. Zhang, L.; Mu, C.; Zhang, T.; Wang, Y.; Wang, Y.; Fan, L.; Liu, C.; Chen, H.; Shen, J.; Wei, K.; et al. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer. ACS Appl. Mater Interfaces 2020, 12, 32360–32371. [Google Scholar] [CrossRef] [PubMed]
  57. Lee, J.; Park, Y.H. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncol. 2022, 18, 7–19. [Google Scholar] [CrossRef]
Pharmaceutics 15 01190 g001 550
Figure 1. Transmission electron micrographs of cationic liposome: siRNA lipoplexes (N/P (+/−) charge ratios): (A) Chol-T; (B) Chol-T 2% PEG2000; (C) Chol-T 5% PEG2000; (D) MS09; (E) MS09 2% PEG22000; (F) MS09 5% PEG2000. Scale Bar = 100 nm (D) or 200 nm (A–C,E,F).
Figure 1. Transmission electron micrographs of cationic liposome: siRNA lipoplexes (N/P (+/−) charge ratios): (A) Chol-T; (B) Chol-T 2% PEG2000; (C) Chol-T 5% PEG2000; (D) MS09; (E) MS09 2% PEG22000; (F) MS09 5% PEG2000. Scale Bar = 100 nm (D) or 200 nm (A–C,E,F).
Pharmaceutics 15 01190 g001
Pharmaceutics 15 01190 g002 550
Figure 2. Band-shift assay showing the binding interaction between varying amounts of PEGylated and non-PEGylated cationic liposomes with siRNA (0.32 μg). (A) Chol-T: Lanes 1–8 (0, 3.20, 3.52, 3.84, 4.16, 4.48, 4.80, and 5.12 μg); (B) Chol-T 2% PEG2000: Lanes 1–8 (0, 6.08, 6.40, 6.72, 7.04, 7.36, 7.68, and 8.00 μg); (C) Chol-T 5% PEG2000: Lanes 1–8 (0, 10.56, 10.88, 11.20, 11.52, 11.84, 12.16, and 12.48 μg); (D) MS09: Lanes 1–8 (0, 5.44, 5.76, 6.08, 6.40, 6.72, 7.04, and 7.36 μg); (E) MS09 2% PEG2000: Lanes 1–8 (0, 6.08, 6.40, 6.72, 7.04, 7.36, 7.68, and 8.00 μg); (F) MS09 5% PEG2000: Lanes 1–8 (0, 9.60, 9.92, 10.24, 10.56, 10.88, 11.20, and 11.52 μg). White arrows indicate endpoint ratios, except in 2F, where it indicates no clear endpoint.
Figure 2. Band-shift assay showing the binding interaction between varying amounts of PEGylated and non-PEGylated cationic liposomes with siRNA (0.32 μg). (A) Chol-T: Lanes 1–8 (0, 3.20, 3.52, 3.84, 4.16, 4.48, 4.80, and 5.12 μg); (B) Chol-T 2% PEG2000: Lanes 1–8 (0, 6.08, 6.40, 6.72, 7.04, 7.36, 7.68, and 8.00 μg); (C) Chol-T 5% PEG2000: Lanes 1–8 (0, 10.56, 10.88, 11.20, 11.52, 11.84, 12.16, and 12.48 μg); (D) MS09: Lanes 1–8 (0, 5.44, 5.76, 6.08, 6.40, 6.72, 7.04, and 7.36 μg); (E) MS09 2% PEG2000: Lanes 1–8 (0, 6.08, 6.40, 6.72, 7.04, 7.36, 7.68, and 8.00 μg); (F) MS09 5% PEG2000: Lanes 1–8 (0, 9.60, 9.92, 10.24, 10.56, 10.88, 11.20, and 11.52 μg). White arrows indicate endpoint ratios, except in 2F, where it indicates no clear endpoint.
Pharmaceutics 15 01190 g002
Pharmaceutics 15 01190 g003 550
Figure 3. Nuclease protection assay of cationic and PEGylated cationic liposome-siRNA complexes in the presence of 10% FBS. Reaction mixtures (10 μL) contained siRNA (0.2 μg) and varying amounts of liposome suspension. (A) Lanes 3–5: Chol-T (2.4, 2.8, 3.2 μg) Lanes 6–8: MS09 (3.8, 4.2, 4.6 μg); (B) Lanes 3–5: Chol-T 2% PEG2000 (4.4, 4.8, 5.2 μg), Lanes 6–8: Chol-T 5% PEG2000 (7.0, 7.4, 7.8 μg); (C) Lanes 3–5: MS09 2% PEG2000 (4.6, 5.0, 5.4 μg), Lanes 6–8: MS09 5% PEG2000 (6.8, 7.2, 7.6 μg). Lane 1: FBS-untreated naked siRNA (0.2 μg) and lane 2: FBS-treated siRNA (0.2 μg).
Figure 3. Nuclease protection assay of cationic and PEGylated cationic liposome-siRNA complexes in the presence of 10% FBS. Reaction mixtures (10 μL) contained siRNA (0.2 μg) and varying amounts of liposome suspension. (A) Lanes 3–5: Chol-T (2.4, 2.8, 3.2 μg) Lanes 6–8: MS09 (3.8, 4.2, 4.6 μg); (B) Lanes 3–5: Chol-T 2% PEG2000 (4.4, 4.8, 5.2 μg), Lanes 6–8: Chol-T 5% PEG2000 (7.0, 7.4, 7.8 μg); (C) Lanes 3–5: MS09 2% PEG2000 (4.6, 5.0, 5.4 μg), Lanes 6–8: MS09 5% PEG2000 (6.8, 7.2, 7.6 μg). Lane 1: FBS-untreated naked siRNA (0.2 μg) and lane 2: FBS-treated siRNA (0.2 μg).
Pharmaceutics 15 01190 g003
Pharmaceutics 15 01190 g004 550
Figure 4. Cell viability studies of siRNA lipoplexes in (A) HEK293, (B) MCF-7, and (C) SKBR-3 cells in vitro. Incubation mixtures contained 0.32 μg of siRNA with varying amounts of liposome from suboptimal to supraoptimal N/P (+:−) charge ratios: Chol-T (3.4, 3.9, 4.4); Chol-T 2% PEG (5.8, 6.3, 6.8); Chol-T 5% PEG (8.3, 8.8, 9.3); MS09 (4.9, 5.4, 5.9); MS09 2% PEG (5.5, 6.0, 6.5); MS09 5% PEG (7.4, 7.9, 8.4). C1 = cells only- untreated), and C2 = Lipofectamine3000 treated cells. Data are presented as means ± SD (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 were considered statistically significant vs. the cell control.
Figure 4. Cell viability studies of siRNA lipoplexes in (A) HEK293, (B) MCF-7, and (C) SKBR-3 cells in vitro. Incubation mixtures contained 0.32 μg of siRNA with varying amounts of liposome from suboptimal to supraoptimal N/P (+:−) charge ratios: Chol-T (3.4, 3.9, 4.4); Chol-T 2% PEG (5.8, 6.3, 6.8); Chol-T 5% PEG (8.3, 8.8, 9.3); MS09 (4.9, 5.4, 5.9); MS09 2% PEG (5.5, 6.0, 6.5); MS09 5% PEG (7.4, 7.9, 8.4). C1 = cells only- untreated), and C2 = Lipofectamine3000 treated cells. Data are presented as means ± SD (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 were considered statistically significant vs. the cell control.
Pharmaceutics 15 01190 g004
Pharmaceutics 15 01190 g005 550
Figure 5. Analysis of HER2/neu gene expression in SKBR-3 cells by qRT-PCR. The vertical axis represents the relative quantification of HER2/neu normalized against GAPDH mRNA level using the comparative quantification algorithm 2-∆∆Ct [30]. The mean ± SD of independent experiments (n = 3). *** p < 0.001 was considered statistically significant.
Figure 5. Analysis of HER2/neu gene expression in SKBR-3 cells by qRT-PCR. The vertical axis represents the relative quantification of HER2/neu normalized against GAPDH mRNA level using the comparative quantification algorithm 2-∆∆Ct [30]. The mean ± SD of independent experiments (n = 3). *** p < 0.001 was considered statistically significant.
Pharmaceutics 15 01190 g005
Pharmaceutics 15 01190 g006 550
Figure 6. Analysis of HER2/neu oncoprotein expression by western blotting. (A) Non-treated SKBR-3 cells, NT-siRNA (non-targeting siRNA), and siRNA (HER2/neu targeting siRNA alone) served as negative controls. Lipofectamine® 3000-siRNA was included as a positive control, (B) SKBR-3 cells were treated with HER2/neu target siRNA: PEGylated and non-PEGylated Chol-T lipoplexes and (C) SKBR-3 cells were treated with HER2/neu target siRNA: PEGylated and non-PEGylated MS09 lipoplexes. HER2/neu receptor expression was determined in cellular lysates by Western blotting analysis using the HER2/neu and β-actin antibodies. Graphs represent the HER2/neu/β-actin normalization ratios. Data are presented as means ± SD (n = 3). **** p < 0.0001 is considered statistically significant vs. the untreated SKBR-3 cell control.
Figure 6. Analysis of HER2/neu oncoprotein expression by western blotting. (A) Non-treated SKBR-3 cells, NT-siRNA (non-targeting siRNA), and siRNA (HER2/neu targeting siRNA alone) served as negative controls. Lipofectamine® 3000-siRNA was included as a positive control, (B) SKBR-3 cells were treated with HER2/neu target siRNA: PEGylated and non-PEGylated Chol-T lipoplexes and (C) SKBR-3 cells were treated with HER2/neu target siRNA: PEGylated and non-PEGylated MS09 lipoplexes. HER2/neu receptor expression was determined in cellular lysates by Western blotting analysis using the HER2/neu and β-actin antibodies. Graphs represent the HER2/neu/β-actin normalization ratios. Data are presented as means ± SD (n = 3). **** p < 0.0001 is considered statistically significant vs. the untreated SKBR-3 cell control.
Pharmaceutics 15 01190 g006
Pharmaceutics 15 01190 g007 550
Figure 7. Comparison of HER2/neu oncogene knockdown of PEGylated and non-PEGylated (A) Chol-T and (B) MS09 lipoplexes vs. Lipofectamine® 3000 following Western Blotting Analysis. Graphs represent the HER2/neu/β-actin normalization ratios. Data are presented as means ± SD (n = 3). * p < 0.1, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 are considered statistically significant vs. Lipofectamine® 3000.
Figure 7. Comparison of HER2/neu oncogene knockdown of PEGylated and non-PEGylated (A) Chol-T and (B) MS09 lipoplexes vs. Lipofectamine® 3000 following Western Blotting Analysis. Graphs represent the HER2/neu/β-actin normalization ratios. Data are presented as means ± SD (n = 3). * p < 0.1, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 are considered statistically significant vs. Lipofectamine® 3000.
Pharmaceutics 15 01190 g007
Table
Table 1. Composition and molar ratios of the different cationic liposomal formulations.
Table 1. Composition and molar ratios of the different cationic liposomal formulations.
Liposomal
Formulation		Molar Ratios of the Respective Cationic Liposome Components (μmol/500 μL)Total Lipid Content (µg/µL)
CytofectinDOPEPEG
Chol-T: DOPE1.001.00-2.517
Chol-T:DOPE:2% PEG1.000.960.042.648
Chol-T:DOPE:5% PEG1.000.900.102.938
MS09:DOPE1.001.00-2.746
MS09:DOPE:2% PEG1.000.960.042.914
MS09:DOPE:5% PEG1.000.900.103.168
Table
Table 2. Varying amounts (µg) of PEGylated and non-PEGylated cationic liposomes were added to siRNA for the band shift assay. Columns 1–8 correspond to the lanes of the agarose gel.
Table 2. Varying amounts (µg) of PEGylated and non-PEGylated cationic liposomes were added to siRNA for the band shift assay. Columns 1–8 correspond to the lanes of the agarose gel.
ComponentsMass (µg)
12345678
Chol-T:DOPE03.203.523.844.164.48 *4.805.12
Chol-T:DOPE:2% PEG06.086.406.727.047.367.68 *8.00
Chol-T:DOPE:5% PEG010.5610.8811.2011.5211.84 *12.1612.48
MS09:DOPE05.445.766.086.406.72 *7.047.36
MS09:DOPE:2% PEG06.086.406.727.047.367.688.00 *
MS09:DOPE:5% PEG09.609.9210.2410.5610.8811.2011.52 *
Endpoints are indicated by an *. Column 1 (lane 1) = siRNA in the absence of cationic liposomes.
Table
Table 3. Lipoplexes at the sub-optimum, optimum and supra-optimum ratios (w/w).
Table 3. Lipoplexes at the sub-optimum, optimum and supra-optimum ratios (w/w).
Liposomal FormulationSub-Optimum Ratio (w/w)Optimum Ratio (w/w)Supra-Optimum Ratio (w/w)
Chol-T1:121:141:16
Chol-T 2% PEG20001:221:241:26
Chol-T 5% PEG20001:351:371:39
MS091:191:211:23
MS09 2% PEG20001:231:251:27
MS09 5% PEG20001:341:361:38
Note: siRNA was kept constant at 0.2 µg.
Table
Table 4. Size, zeta (ζ) potential, and polydispersity indices (PDI) of the cationic liposomes and their complexes with siRNA at their optimum binding ratios (w/w).
Table 4. Size, zeta (ζ) potential, and polydispersity indices (PDI) of the cationic liposomes and their complexes with siRNA at their optimum binding ratios (w/w).
Cationic LiposomeLiposomesiRNA Lipoplex
Size (nm)ζ Potential (mV) ± SDPDISize (nm)ζ Potential (mV) ± SDPDI
Chol-T121.07 ± 11.844.09 ± 10.560.321187.97 ± 12.947.26 ± 5.390.127
Chol-T 2% PEG71.64 ± 2.6 32.51 ± 11.020.304149.61 ± 10.539.05 ± 8.160.227
Chol-T 5% PEG74.18 ± 1.9–1.12 ± 4.8180.136153.24 ± 18.99.78 ± 1.130.109
MS09113.02 ± 13.553.21 ± 4.3290.348169.13 ± 19.244.61 ± 7.560.326
MS09 2% PEG66.68 ± 1.739.43 ± 1.1850.136103.24 ± 9.120.88 ± 3.0520.218
MS09 5% PEG65.47 ±1.3 16.08 ± 3.7990.269138.64 ± 10.241.26 ± 9.790.337
Table
Table 5. Band-shift assay endpoints and charge ratios of the various cationic/PEGylated cationic liposomes.
Table 5. Band-shift assay endpoints and charge ratios of the various cationic/PEGylated cationic liposomes.
Cationic LiposomesiRNA: Cationic Liposome Endpoint (w/w)NP Charge Ratio (+/−)
Chol-T1:141:3.9
Chol-T 2% PEG20001:241:6.3
Chol-T 5% PEG20001:371:8.8
MS091:211:5.4
MS09 2% PEG20001:251:6.0
MS09 5% PEG20001:361:7.9
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Balgobind, A.; Daniels, A.; Ariatti, M.; Singh, M. HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems. Pharmaceutics 2023, 15, 1190. https://doi.org/10.3390/pharmaceutics15041190

AMA Style

Balgobind A, Daniels A, Ariatti M, Singh M. HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems. Pharmaceutics. 2023; 15(4):1190. https://doi.org/10.3390/pharmaceutics15041190

Chicago/Turabian Style

Balgobind, Adhika, Aliscia Daniels, Mario Ariatti, and Moganavelli Singh. 2023. "HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems" Pharmaceutics 15, no. 4: 1190. https://doi.org/10.3390/pharmaceutics15041190

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop